SLC22A13: A Potential Drug Target and Biomarker (G9390)

Target Name: SLC22A13

NCBI ID: G9390

SLC22A13

SLC22A13: A Potential Drug Target and Biomarker

Solute carrier family 22 (SLC22) is a family of proteins that play a crucial role in the transport of various anions, including organic anions, across cell membranes. One of the SLC22 proteins, SLC22A13, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. In this article, we will discuss the biology of SLC22A13, its potential drug targets, and its potential as a biomarker for certain diseases.

Biography of SLC22A13

SLC22A13 is a member of the SLC22 family of proteins, which are known to transport a wide variety of anions across cell membranes. These anions include essential nutrients, such as glucose and amino acids, as well as toxins and other harmful substances that need to be excluded from the cell. SLC22A13 is a 22kDa protein that has four transmembrane domains: an N-terminus, a C-terminus, a T-terminus, and an R-terminus.

Function of SLC22A13

SLC22A13 is involved in the transport of a wide variety of organic anions across cell membranes. It has been shown to transport a variety of anions, including:

* Acetylcholine: an neurotransmitter involved in muscle contractions and cognitive function
* K+: a vital ion that regulates muscle and nerve function
* Na+: a vital ion that regulates muscle and nerve function
* Cl-: a crucial ion that helps maintain the electrical balance of the cell
* Br-: a crucial ion that helps maintain the electrical balance of the cell
* I-: a trace ion that plays a role in the regulation of cell growth and differentiation

SLC22A13 is also involved in the regulation of intracellular ion levels, which is critical for maintaining proper signaling and cellular function.

Potential Drug Target

SLC22A13 has been identified as a potential drug target due to its involvement in the regulation of various signaling pathways. One of the primary signaling pathways that SLC22A13 is involved in is the regulation of pain perception. SLC22A13 has been shown to play a critical role in the regulation of pain perception by transporting neurotransmitters, such as opioids, across cell membranes.

In addition to its role in pain perception, SLC22A13 is also involved in the regulation of other signaling pathways that are important for cellular function. For example, SLC22A13 is involved in the regulation of ion channels, which are critical for the proper functioning of cells. Additionally, SLC22A13 is involved in the regulation of protein synthesis and cellular growth, which are critical for cellular growth and development.

Potential Biomarker

SLC22A13 has also been identified as a potential biomarker for various neurological and psychiatric disorders. For example, SLC22A13 has been shown to be involved in the regulation of glutamate, a neurotransmitter that is involved in neurotransmission. Additionally, SLC22A13 has been shown to play a critical role in the regulation of ion channels, which are critical for the proper functioning of cells.

In conclusion, SLC22A13 is a highly conserved protein that is involved in the transport of various anions across cell membranes. Its function in the regulation of pain perception and other signaling pathways makes it a potential drug target. In addition, its potential as a biomarker for various neurological and psychiatric disorders makes it an attractive candidate for further research. Further studies are needed to fully understand the role of SLC22A13 in

Protein Name: Solute Carrier Family 22 Member 13

Functions: Anion antiporter that mediates the transport of urate, orotate and nicotinate in exchange for organic or inorganic anions (PubMed:18411268, PubMed:35144162, PubMed:31780526, PubMed:35462902). Translocates urate and orotate across the apical membrane of proximal tubule epithelial cells and involved in urate renal reabsorption (PubMed:18411268, PubMed:35144162, PubMed:31780526). Possibly involved in orotate renal reabsorption and nicotinate intestinal reabsorption (PubMed:18411268, PubMed:35144162). Mediates urate uptake by an exchange with organic anions such as (S)-lactate, succinate, glutathione and nicotinate (PubMed:18411268). Urate and orotate transports are Cl(-)-dependent (PubMed:35144162, PubMed:35462902). Shows similar transport characteristics as the urate/orotate renal antiporter SLC22A12/URAT1 and may act as a compensator of SLC22A12/URAT1 in certain conditions (Probable)

The "SLC22A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets